Celgene Slips; Drug Candidate Fails Phase III Trial Endpoint
July 09, 2014 at 09:37 AM EDT
Celgene's (NASDAQ: CELG) shares slipped nearly two percent in pre-market trading after the company said its drug candidate for ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.